

28 March 2024

**Advanced Medical Solutions Group plc**  
("AMS" or the "Group")

**Total Voting Rights**

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 28 March 2024 comprises 217,341,362 ordinary shares of 5p each with voting rights. There are no shares held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

- Ends -

For further information, please visit [www.admedsol.com](http://www.admedsol.com) or contact:

**Advanced Medical Solutions Group plc**  
Chris Meredith, Chief Executive Officer  
Eddie Johnson, Chief Financial Officer  
Michael King, Investor Relations

Tel: +44 (0) 1606 545508

**ICR Consilium**  
Mary-Jane Elliott / Lucy Featherstone

Tel: +44 (0) 20 3709 5700  
[AMS@consilium-comms.com](mailto:AMS@consilium-comms.com)

**Investec Bank plc (NOMAD and Broker)**  
Gary Clarence / David Anderson

Tel: +44 (0) 20 7597 5970

**HSBC Bank plc (Broker)**  
Sam McLennan / Joe Weaving / Stephanie Cornish

Tel: 44 (0) 20 7991 8888

**About Advanced Medical Solutions Group plc**

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies; Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products; AFS Medical, an Austrian a specialist surgical business with a focus on minimally invasive procedures, and Connexicon Medical, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France, Ireland and Israel. Established in 1991, the Group has more than 900 employees. For more information, please see [www.admedsol.com](http://www.admedsol.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVREAXDPAEALEFA